In recent years, GnRH-antagonist therapy has been proposed as the first-line protocol for COH in women with PCOS because antagonist can clearly reduce the risk of Ovarian Hyperstimulation Syndrome (OHSS) [19,20,21]. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.